Medical Oncology

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


960 publications

In press | 2024 | 2023 | 2022 | ...
In press
 
Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy.
Berezowska S., Keyter M., Bouchaab H., Weissferdt A. Advances in anatomic pathology. Peer-reviewed.
[DOI][Pmid][serval:BIB_9497567AE341]
 
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
de Joode K., Mora A.R., van Schaik RHN, Zippelius A., van der Veldt A., Gerard C.L., Läubli H., Michielin O., von Moos R., Joerger M. et al. Journal of immunotherapy. Peer-reviewed.
[DOI][Pmid][serval:BIB_B6930E6F147C]
 
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Garon E.B., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Trukhin D., Kim S.W., Ursol G., Hussein M., Lim F.L. et al. Clinical lung cancer. Peer-reviewed.
[DOI][Pmid][serval:BIB_7A92BC1E6EB4]
 
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
Guarneri V., Passos Coelho J.L., Duhoux F.P., Egle D., García-Sáenz J.Á., Penault-Llorca F., Selander K., Wildiers H., Zaman K., Laeis P. et al. Future oncology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7A3D7ED540BF]
 
Melanoma clonal heterogeneity leads to secondary resistance after adoptive cell therapy with tumor-infiltrating lymphocytes.
König D., Sandholzer M., Uzun S., Zingg A., Ritschard R., Thut H., Glatz K., Kappos E.A., Schaefer D.J., Kettelhack C. et al. Cancer immunology research. Peer-reviewed.
[DOI][Pmid][serval:BIB_43CB67C6DE73]
 
Recurrent benign fibrous histiocytoma of the bone benefits from denosumab followed by malignant transformation: a case report.
Laureline W., Patrick O., Tu N., Stephane C., Ana D., Daniela F., Chiara S., Igor L., Antonia D. Skeletal radiology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_22489F1FC523]
 
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Pal S.K., Tran B., Haanen JBAG, Hurwitz M.E., Sacher A., Tannir N.M., Budde L.E., Harrison S.J., Klobuch S., Patel S.S. et al. Cancer discovery. Peer-reviewed.
[DOI][Pmid][serval:BIB_380D2196CD9C]
 
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond.
Stravodimou A., Voutsadakis I.A. Expert review of anticancer therapy pp. 1-19. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8D56E74D4A72]
2024
Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database
Baliga Sujith, Abou-Foul Ahmad K., Parente Pablo, Szturz Petr, Thariat Juliette, Shreenivas Aditya, Nankivell Paul, Bertolini Federica, Biau Julian, Blakaj Dukagjin et al., 2024/05. European Journal of Cancer, 203 p. 114038. Peer-reviewed.
[DOI][Pmid][serval:BIB_D13A76D5865C]
 
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Peters S., Angevin E., Alonso-Gordoa T., Rohrberg K., Melero I., Mellado B., Perez-Gracia J.L., Tabernero J., Adessi C., Boetsch C. et al., 2024/04/15. Clinical cancer research, 30 (8) pp. 1630-1641. Peer-reviewed.
[DOI][Pmid][serval:BIB_CC842A12DADF]
 
Melanoma neoantigen vaccines: Are we getting more personal now?
Latifyan S., Haanen J.B., 2024/04/12. Med, 5 (4) pp. 288-290. Peer-reviewed.
[DOI][Pmid][serval:BIB_362339C5E2F1]
 
Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now.
Passaro A., Peters S., 2024/04/11. The New England journal of medicine, 390 (14) pp. 1325-1327. Peer-reviewed.
[DOI][Pmid][serval:BIB_A545924B1B46]
 
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.
Verkerk K., Geurts B.S., Zeverijn L.J., van der Noort V., Verheul HMW, Haanen JBAG, van der Veldt AAM, Eskens FALM, Aarts MJB, van Herpen CML et al., 2024/04. The Lancet regional health. Europe, 39 p. 100875. Peer-reviewed.
[DOI][Pmid][serval:BIB_FB1F09F33DB5]
 
Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey.
Comoli P., Pentheroudakis G., Ruggeri A., Koehl U., Lordick F., Mooyaart J.E., Hoogenboom J.D., Urbano-Ispizua A., Peters S., Kuball J. et al., 2024/04. Annals of oncology, 35 (4) pp. 404-406. Peer-reviewed.
[DOI][Pmid][serval:BIB_C8DF2F8D0C82]
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
Vicino A., Hottinger A.F., Latifyan S., Boughdad S., Becce F., Prior J.O., Kuntzer T., Brouland J.P., Dunet V., Obeid M. et al., 2024/04. Journal of neurology, 271 (4) pp. 1947-1958. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_29F8761FAE12]
 
Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment.
Costamagna G., Navi B.B., Beyeler M., Hottinger A.F., Alberio L., Michel P., 2024/04. Seminars in thrombosis and hemostasis, 50 (3) pp. 342-359. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB89FEB62E93]
 
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
Kyriazoglou A., Pagkali A., Kotsantis I., Economopoulou P., Kyrkasiadou M., Moutafi M., Gavrielatou N., Anastasiou M., Boulouta A., Pantazopoulos A. et al., 2024/04. Cancer treatment reviews, 125 p. 102716. Peer-reviewed.
[DOI][Pmid][serval:BIB_CB408536C633]
 
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.
Passaro A., Al Bakir M., Hamilton E.G., Diehn M., André F., Roy-Chowdhuri S., Mountzios G., Wistuba I.I., Swanton C., Peters S., 2024/03/28. Cell, 187 (7) pp. 1617-1635. Peer-reviewed.
[DOI][Pmid][serval:BIB_BA8F740FDA43]
 
Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted hydration in patients with advanced cancer.
Hayes J., Bruera E., Crawford G., Fleury M., Santos M., Thompson J., Davies A., 2024/03/13. Supportive care in cancer, 32 (4) p. 228. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4B4960C77E68]
Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms.
Bejarano L., Kauzlaric A., Lamprou E., Lourenco J., Fournier N., Ballabio M., Colotti R., Maas R., Galland S., Massara M. et al., 2024/03/11. Cancer cell, 42 (3) pp. 378-395.e10. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3AD4E56F8FEC]
 
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor A.M., McKeown J., Dimitriou F., Jacques S.K., Zimmer L., Allayous C., Yeoh H.L., Haydon A., Ressler J.M., Galea C. et al., 2024/03. European journal of cancer, 199 p. 113561. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB58FC4C5C60]
 
Immunohistochemical expression of HMGB1 and related proteins in the skin as a possible tool for determining post-mortem interval: a preclinical study.
De-Giorgio F., Bergamin E., Baldi A., Gatta R., Pascali V.L., 2024/03. Forensic science, medicine, and pathology, 20 (1) pp. 149-165. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D91E32B109C2]
 
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
Jacques S.K., McKeown J., Grover P., Johnson D.B., Zaremba A., Dimitriou F., Weiser R., Farid M., Namikawa K., Sullivan R.J. et al., 2024/03. European journal of cancer, 199 p. 113563. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AD78846E78A2]
 
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.
Klobuch S., Seijkens TTP, Schumacher T.N., Haanen JBAG, 2024/03. Nature reviews. Clinical oncology, 21 (3) pp. 173-184. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DD86B14A7D89]
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.
Herrstedt J., Clark-Snow R., Ruhlmann C.H., Molassiotis A., Olver I., Rapoport B.L., Aapro M., Dennis K., Hesketh P.J., Navari R.M. et al., 2024/02. ESMO open, 9 (2) p. 102195. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_87AB27244127]
 
Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned.
Borgers JSW, van Schijndel A.W., van Thienen J.V., Klobuch S., Seijkens TTP, Tobin R.P., van Heerebeek L., Driessen-Waaijer A., Rohaan M.W., Haanen JBAG, 2024/02. ESMO open, 9 (2) p. 102383. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_11666E481B80]
 
First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
Uprety D., Remon J., Peters S., 2024/02/01. Journal of clinical oncology, 42 (4) pp. 378-382. Peer-reviewed.
[DOI][Pmid][serval:BIB_FCBB794FB641]
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Peters S., Trigo J., Besse B., Moreno V., Navarro A., Eugenia Olmedo M., Paz-Ares L., Grohé C., Antonio Lopez-Vilariño J., Fernández C. et al., 2024/02. Lung cancer, 188 p. 107448. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_251547356E4A]
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor Y.L., van de Haar J., van den Berg J.G., van Sandick J.W., Kodach L.L., van Dieren J.M., Balduzzi S., Grootscholten C., IJsselsteijn M.E., Veenhof AAFA et al., 2024/02. Nature medicine, 30 (2) pp. 519-530. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CFF0D10D1EFA]
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.
Harbeck N., Wrobel D., Zaiss M., Terhaag J., Guth D., Distelrath A., Zahn M.O., Wuerstlein R., Lorenz A., Bartsch R. et al., 2024/02. Breast care, 19 (1) pp. 1-9. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B7502F26CC0C]
 
Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023.
Ringborg U., von Braun J., Celis J., Baumann M., Berns A., Eggermont A., Heard E., Heitor M., Chandy M., Chen C.J. et al., 2024/02. Molecular oncology, 18 (2) pp. 245-279. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E812852CFCF3]
Anatomical Quantitative Volumetric Evaluation of Liver Segments in Hepatocellular Carcinoma Patients Treated with Selective Internal Radiation Therapy: Key Parameters Influencing Untreated Liver Hypertrophy.
Girardet R., Knebel J.F., Dromain C., Vietti Violi N., Tsoumakidou G., Villard N., Denys A., Halkic N., Demartines N., Kobayashi K. et al., 2024/01/30. Cancers, 16 (3). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_190E90C12E5E]
CIC-DUX4 Chromatin Profiling Reveals New Epigenetic Dependencies and Actionable Therapeutic Targets in CIC-Rearranged Sarcomas.
Bakaric A., Cironi L., Praz V., Sanalkumar R., Broye L.C., Favre-Bulle K., Letovanec I., Digklia A., Renella R., Stamenkovic I. et al., 2024/01/21. Cancers, 16 (2) p. 457. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6DD2EB3D2A00]
 
Oncologie: ce qui a changé en 2023 [Oncology: what's new in 2023]
Jankovic J., Abdelhamid K., Berthold D., Desbaillets N., Bouchaab H., Dei Tos G., Demicheli R., Diciolla A., Digklia A., Ferraro D.A. et al., 2024/01/17. Revue medicale suisse, 20 (856-7) pp. 80-87. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_126B4D3C8255]
 
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Mastall M., Roth P., Bink A., Fischer Maranta A., Läubli H., Hottinger A.F., Hundsberger T., Migliorini D., Ochsenbein A., Seystahl K. et al., 2024/01/15. BMC cancer, 24 (1) p. 82. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5EBA66D24C63]
A Review of Ultrasound-Mediated Checkpoint Inhibitor Immunotherapy.
Rivera J., Digklia A., Christou A.S., Anibal J., Vallis K.A., Wood B.J., Stride E., 2024/01. Ultrasound in medicine & biology, 50 (1) pp. 1-7. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E69D2EA7A395]
 
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
Gridelli C., Peters S., Mok T., Garassino M., Paz-Ares L., Attili I., de Marinis F., 2024/01. Lung cancer, 187 p. 107441. Peer-reviewed.
[DOI][Pmid][serval:BIB_9749AF3A1EE0]
 
Reirradiation of head and neck squamous cell carcinomas: a pragmatic approach-part I: prognostic factors and indications to treatment.
Alterio D., Zaffaroni M., Bossi P., Dionisi F., Elicin O., Falzone A., Ferrari A., Jereczek-Fossa B.A., Sanguineti G., Szturz P. et al., 2024/01. La Radiologia medica, 129 (1) pp. 160-173. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1B37A4813CBC]
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Digklia A., Kollár A., Dietrich D., Kronig M.N., Britschgi C., Rordorf T., Joerger M., Krasniqi F., Metaxas Y., Colombo I. et al., 2024/01. European journal of cancer, 197 p. 113470. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F4C4A8A8D1EB]
 
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H., de Marinis F., Dumoulin D., Reynolds C., Theelen WSME, Percent I., Gutierrez Calderon V., Johnson M.L., Madroszyk-Flandin A., Garon E.B. et al., 2024/01. Annals of oncology, 35 (1) pp. 66-76. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1ED7B5418D24]
2023
Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
Anchisi S., Wolfer A., Bisig B., Missiglia E., Tiab A., Kamel E.M., Michielin O., Coukos G., Homicsko K., 2023/12/31. Cancer biology & therapy, 24 (1) p. 2193116. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_365141E36CC9]
 
5-Fluorouracil-associated severe hypertriglyceridaemia with positive rechallenge.
Giacomuzzi Moore B., Durigova A., Lamine F., Chtioui H., Salati E., 2023/12/19. BMJ case reports, 16 (12). Peer-reviewed.
[DOI][Pmid][serval:BIB_E970BBCD043C]
 
2023 MASCC/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies.
Molassiotis A., Affronti M.L., Fleury M., Olver I., Giusti R., Scotte F., 2023/12/16. Supportive care in cancer, 32 (1) p. 30. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_68A5B066F8D9]
 
Diagnostic et prise en charge de la tumeur à cellules géantes ténosynoviale [Diagnosis and management of tenosynovial giant cell tumor]
Bakota-Morrison C., Strasser R., Letovanec I., Digklia A., Stamatiou A., Omoumi P., Cherix S., 2023/12/13. Revue medicale suisse, 19 (854) pp. 2330-2335. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E70F81166152]
 
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Zeng Q., Klein C., Caruso S., Maille P., Allende D.S., Mínguez B., Iavarone M., Ningarhari M., Casadei-Gardini A., Pedica F. et al., 2023/12. The Lancet. Oncology, 24 (12) pp. 1411-1422. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5B5A44DC3272]
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).
Burns L., Hsu C.Y., Whisenant J.G., Marmarelis M.E., Presley C.J., Reckamp K.L., Khan H., Jo Fidler M., Bestvina C.M., Brahmer J. et al., 2023/12. Lung cancer, 186 p. 107423. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_399574E2CC5C]
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon E.B., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Kim S.W., Ursol G., Hussein M., Lim F.L., Yang C.T. et al., 2023/12. Lung cancer, 186 p. 107422. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_709D1EB4530B]
 
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R., Rothschild S.I., Hayoz S., Bubendorf L., Özdemir B.C., Kiss B., Erdmann A., Aeppli S., Mach N., Strebel R.T. et al., 2023/11/20. Journal of clinical oncology, 41 (33) pp. 5131-5139. Peer-reviewed.
[DOI][Pmid][serval:BIB_A7A5826347FE]
 
Dépistage du cancer pulmonaire : vers l’implémentation d’un projet pilote en Suisse [Lung cancer screening : towards the implementation of a pilot project in Switzerland]
Bongard C., Rey Cobo J., Messe R., Noirez L., Lovis A., Krueger T., Peters S., Pozzessere C., Selby K., von Garnier C., 2023/11/15. Revue medicale suisse, 19 (850) pp. 2165-2171. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_C20779B2000E]
 
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.
Lim S.M., Peters S., Ortega Granados A.L., Pinto GDJ, Fuentes C.S., Lo Russo G., Schenker M., Ahn J.S., Reck M., Szijgyarto Z. et al., 2023/11/11. Nature communications, 14 (1) p. 7301. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D6E420A37DBF]
 
Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170.
Margalit O., Harmsen W.S., Shacham-Shmueli E., Voss M.M., Boursi B., Wagner A.D., Cohen R., Olswold C.L., Saltz L.B., Goldstein D.A. et al., 2023/11. European journal of cancer, 194 p. 113339. Peer-reviewed.
[DOI][Pmid][serval:BIB_F88116DF20BF]
 
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
Kim H.R., Awad M.M., Navarro A., Gottfried M., Peters S., Csőszi T., Cheema P.K., Rodriguez-Abreu D., Wollner M., Yang J.C. et al., 2023/11. JTO clinical and research reports, 4 (11) p. 100572. Peer-reviewed.
[DOI][Pmid][serval:BIB_7EBE3AF70615]
Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report.
Wolf B., Dunet V., Dubruc E., Dolcan A., Nicod Lalonde M., Schiappacasse L., Zaman K., 2023/11. Case reports in oncology, 16 (1) pp. 1425-1435. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_7C9285AA6C6A]
The local microenvironment drives activation of neutrophils in human brain tumors.
Maas R.R., Soukup K., Fournier N., Massara M., Galland S., Kornete M., Wischnewski V., Lourenco J., Croci D., Álvarez-Prado Á.F. et al., 2023/10/12. Cell, 186 (21) pp. 4546-4566.e27. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_698367BEBBF8]
 
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S., Bianchi V., Tanyi J.L., Sarivalasis A., Missiaglia E., Pétremand R., Benedetti F., Torigian D.A., Genolet R., Barras D. et al., 2023/10. Nature cancer, 4 (10) pp. 1410-1417. Peer-reviewed.
[DOI][Pmid][serval:BIB_E6692BB52E6C]
Cellular Therapy in NSCLC: Between Myth and Reality.
Imbimbo M., Wetterwald L., Friedlaender A., Parikh K., Addeo A., 2023/10. Current oncology reports, 25 (10) pp. 1161-1174. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2233B843CCB3]
 
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U., Fehr M., Schär S., Dreyling M., Schmidt C., Derenzini E., Zander T., Hess G., Mey U., Ferrero S. et al., 2023/10. EClinicalMedicine, 64 p. 102221. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B8178ECC6BDA]
 
ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe.
Bayle A., Bonastre J., Chaltiel D., Latino N., Rouleau E., Peters S., Galotti M., Bricalli G., Besse B., Giuliani R., 2023/10. Annals of oncology, 34 (10) pp. 934-945. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BB80FB84CE17]
 
Gender differences in tumor characteristics, treatment and survival of colorectal cancer: A population-based study.
van Erning F.N., Greidanus NEM, Verhoeven RHA, Buijsen J., de Wilt H.W., Wagner D., Creemers G.J., 2023/10. Cancer epidemiology, 86 p. 102441. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_639F911C9D12]
 
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.
Mountzios G., Remon J., Hendriks LEL, García-Campelo R., Rolfo C., Van Schil P., Forde P.M., Besse B., Subbiah V., Reck M. et al., 2023/10. Nature reviews. Clinical oncology, 20 (10) pp. 664-677. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0FB0D505E36B]
 
Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Le Rhun E., Weller M., van den Bent M., Brandsma D., Furtner J., Rudà R., Schadendorf D., Seoane J., Tonn J.C., Wesseling P. et al., 2023/10. ESMO open, 8 (5) p. 101624. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3F6C44F4DCB8]
 
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
Kristeleit R., Leary A., Delord J.P., Moreno V., Oaknin A., Castellano D., Shappiro G.I., Fernández C., Kahatt C., Alfaro V. et al., 2023/10. Investigational new drugs, 41 (5) pp. 677-687. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_124EFD9C766F]
 
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K., Zygoura P., Norkin M., Tissot S., Shakarishvili N., Popat S., Curioni-Fontecedro A., O'Brien M., Pope A., Shah R. et al., 2023/10. Journal for immunotherapy of cancer, 11 (10). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_03AE420D2700]
Response to letter entitled: letter comments on: Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
Gosney J.R., Peters S., 2023/10. ESMO open, 8 (5) p. 101828. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E0A055E006B6]
 
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
Gulati Shuchi, Hsu Chih-Yuan, Shah Surbhi, Shah Pankil K., Zon Rebecca, Alsamarai Susan, Awosika Joy, El-Bakouny Ziad, Bashir Babar, Beeghly Alicia et al., 2023/10/01. JAMA Oncology, 9 (10) p. 1390.
[DOI][WoS][Pmid][serval:BIB_12CBCEF74E70]
 
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Orlando V., Drubay D., Lavaud P., Faivre L., Lesaunier F., Delva R., Gravis G., Rolland F., Priou F., Ferrero J.M. et al., 2023/10. Clinical genitourinary cancer, 21 (5) pp. 615.e1-615.e8. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2588BC824A41]
Elevated liver function tests in a patient with breast cancer.
Neftel C., Zaman K., Chtioui H., Moradpour D., Sempoux C., Fraga M., 2023/09. Journal of hepatology, 79 (3) pp. e109-e111. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E70D878557D9]
Esophageal cancer T-staging on MRI: A preliminary study using cine and static MR sequences.
Haefliger L., Jreige M., Du Pasquier C., Ledoux J.B., Wagner D., Mantziari S., Shäfer M., Vietti Violi N., Dromain C., 2023/09. European journal of radiology, 166 p. 111001. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B3DB02D052A3]
 
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
Opitz I., Bille A., Dafni U., Nackaerts K., Ampollini L., de Perrot M., Brcic L., Nadal E., Syrigos K., Gray S.G. et al., 2023/09. Journal of thoracic oncology, 18 (9) pp. 1233-1247. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_82EE065BEEA5]
Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?
Haddad R.I., Harrington K., Tahara M., Szturz P., Le Tourneau C., Salmio S., Bajars M., Lee N.Y., 2023/09. Cancer treatment reviews, 119 p. 102585. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5948D827C4E9]
 
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff I.K., van den Bent M.J., Blumenthal D.T., Touat M., Peters K.B., Clarke J., Mendez J., Yust-Katz S., Welsh L., Mason W.P. et al., 2023/08/17. The New England journal of medicine, 389 (7) pp. 589-601. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0F3E3EF3CEF5]
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
Templeton A.J., Omlin A., Berthold D., Beyer J., Burger I.A., Eberli D., Engeler D., Fankhauser C., Fischer S., Gillessen S. et al., 2023/08/15. Swiss medical weekly, 153 p. 40108. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6C5E890FD075]
99mTc-macroaggregated albumin SPECT/CT predictive dosimetry and dose-response relationship in uveal melanoma liver metastases treated with first-line selective internal radiation therapy.
Tabotta F., Gnesin S., Dunet V., Ponti A., Digklia A., Boughdad S., Schaefer N., Prior J.O., Villard N., Tsoumakidou G. et al., 2023/08/12. Scientific reports, 13 (1) p. 13118. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_21F17BF36DB0]
 
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee S.M., Schulz C., Prabhash K., Kowalski D., Szczesna A., Han B., Rittmeyer A., Talbot T., Vicente D., Califano R. et al., 2023/08/05. Lancet, 402 (10400) pp. 451-463. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4B87FA7A77E6]
 
Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
Passaro A., Mok TSK, Attili I., Wu Y.L., Tsuboi M., de Marinis F., Peters S., 2023/08/01. JAMA oncology, 9 (8) pp. 1124-1131. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_30B1F260B901]
 
Learning lessons from the COVID-19 pandemic for real-world evidence research in oncology-shared perspectives from international consortia.
Castelo-Branco L., Lee R., Brandão M., Cortellini A., Freitas A., Garassino M., Geukens T., Grivas P., Halabi S., Oliveira J. et al., 2023/08. ESMO open, 8 (4) p. 101596. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5A744A2C49A9]
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
Hertler C., Felsberg J., Gramatzki D., Le Rhun E., Clarke J., Soffietti R., Wick W., Chinot O., Ducray F., Roth P. et al., 2023/08. European journal of cancer, 189 p. 112913. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_58117B8EE829]
Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy.
Courlet P., Abler D., Guidi M., Girard P., Amato F., Vietti Violi N., Dietz M., Guignard N., Wicky A., Latifyan S. et al., 2023/08. CPT, 12 (8) pp. 1170-1181. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A319336A78BD]
 
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
Gosney J.R., Paz-Ares L., Jänne P., Kerr K.M., Leighl N.B., Lozano M.D., Malapelle U., Mok T., Sheffield B.S., Tufman A. et al., 2023/08. ESMO open, 8 (4) p. 101587. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0803E2B8A7EF]
 
Reirradiation of head and neck squamous cell carcinomas: a pragmatic approach, part II: radiation technique and fractionations.
Alterio D., Zaffaroni M., Bossi P., Dionisi F., Elicin O., Falzone A., Ferrari A., Jereczek-Fossa B.A., Sanguineti G., Szturz P. et al., 2023/08. La Radiologia medica, 128 (8) pp. 1007-1021. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_89918BD1D7ED]
 
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
Proto C., Manglaviti S., Lo Russo G., Musca M., Galli G., Imbimbo M., Perrino M., Cordua N., Rulli E., Ballatore Z. et al., 2023/08. Journal of thoracic oncology, 18 (8) pp. 1070-1081. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F9F91FE5CC5]
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Reck M., Ciuleanu T.E., Lee J.S., Schenker M., Zurawski B., Kim S.W., Mahave M., Alexandru A., Peters S., Pluzanski A. et al., 2023/08. Journal of thoracic oncology, 18 (8) pp. 1055-1069. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9890E6F11421]
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors.
da Silva Lopes A.M., Colomer-Lahiguera S., Darnac C., Giacomini S., Bugeia S., Gutknecht G., Spurrier-Bernard G., Aedo-Lopez V., Mederos N., Latifyan S. et al., 2023/07/22. Supportive care in cancer, 31 (8) p. 484. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EC47A57CA4E0]
 
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
Passaro A., Jänne P.A., Peters S., 2023/07/20. Journal of clinical oncology, 41 (21) pp. 3747-3761. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D5BA313EAC7F]
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
König D., Savic Prince S., Hayoz S., Zens P., Berezowska S., Jochum W., Stauffer E., Braunersreuther V., Trachsel B., Thierstein S. et al., 2023/07/11. ESMO open, 8 (4) p. 101595. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_91D42041CEAF]
 
Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Gogate A., Bennett B., Poonja Z., Stewart G., Medina Colmenero A., Szturz P., Carrington C., Castro C., Gemmen E., Lau A. et al., 2023/07/09. Cancers, 15 (14) p. 3552. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_95F216A17E04]
Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study.
Kalff M.C., Dijksterhuis WPM, Wagner A.D., Oertelt-Prigione S., Verhoeven RHA, Lemmens VEPP, van Laarhoven HWM, Gisbertz S.S., van Berge Henegouwen M.I., 2023/07. European journal of cancer, 187 pp. 114-123. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5B8DD083A7EC]
The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.
Sun X., Abrahamson P., Ballew N., Kalilani L., Phiri K., Bell K.F., Slowley A., Zajac M., Hofstatter E., Stojadinovic A. et al., 2023/07. Cancer investigation, 41 (6) pp. 571-592. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F4BE601CAEA2]
 
Attracting Cavities 2.0: Improving the Flexibility and Robustness for Small-Molecule Docking.
Röhrig U.F., Goullieux M., Bugnon M., Zoete V., 2023/06/26. Journal of chemical information and modeling, 63 (12) pp. 3925-3940. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_38F1AA57EFDC]
 
Effects of food-based interventions in the management of chemoradiotherapy-induced nausea and vomiting: a systematic review.
Molassiotis A., Zhao I.Y., Crichton M., Olver I., Fleury M., Giusti R., Scotte F., Affronti M.L., 2023/06/23. Supportive care in cancer, 31 (7) p. 413. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F265AB431AEB]
 
Clinical and Demographic Characteristics, Mechanisms, and Outcomes in Patients With Acute Ischemic Stroke and Newly Diagnosed or Known Active Cancer.
Costamagna G., Hottinger A., Milionis H., Lambrou D., Salerno A., Strambo D., Livio F., Navi B.B., Michel P., 2023/06/13. Neurology, 100 (24) pp. e2477-e2489. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0F3BF5CF7627]
 
Outcomes of Stage IIIa and Well-Selected Stage IIIb or Oligometastatic Stage IV Non-Small Cell Lung Cancers Managed by Multimodal Therapy Including Immunotherapy and Surgery
Forster C, Abdelnour-Berchtold E, Chriqui L E, Bouchaab H, Peters S, Gonzalez M, Krueger T, Perentes J Y, 2023/06/09. dans British Journal of Surgery.
[DOI][WoS][serval:BIB_B98147D74089]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
 
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases.
Martin P., Tsourti Z., Ribeiro J., Castelo-Branco L., de Azambuja E., Gennatas S., Rogado J., Sekacheva M., Šušnjar S., Viñal D. et al., 2023/06. ESMO open, 8 (3) p. 101566. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_94155F804FBD]
 
Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies.
Godinho R., Noto A., Fenwick C., Stravodimou A., Hugelshofer S., Peters S., Hullin R., Obeid M., 2023/06. Journal for immunotherapy of cancer, 11 (6). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D3B4F544BDF7]
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer.
Saesen R., Van Hemelrijck M., Bogaerts J., Booth C.M., Cornelissen J.J., Dekker A., Eisenhauer E.A., Freitas A., Gronchi A., Hernán M.A. et al., 2023/06. European journal of cancer, 186 pp. 52-61. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A0B1CC3E26F8]
 
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.
Girard N., Ponce Aix S., Cedres S., Berghmans T., Burgers S., Toffart A.C., Popat S., Janssens A., Gervais R., Hochstenbag M. et al., 2023/06. ESMO open, 8 (3) p. 101576. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B5CFBB1D0A86]
 
Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity.
Zurcher Jean-Philippe, Goujon Morgan, Cottu Paul H., Desmoulins Isabelle, Teixeira Luis, Mansi Laura, Meynard Guillaume, Dobi Erion, Rowinski Elise, Stacoffe Marion et al., 2023/06/01. Journal of Clinical Oncology, 41 (16_suppl) pp. e13067-e13067. Peer-reviewed.
[DOI][serval:BIB_B01DDDA0C38A]
 
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
Garbe C., Dummer R., Amaral T., Amaria R.N., Ascierto P.A., Burton E.M., Dreno B., Eggermont AMM, Hauschild A., Hoeller C. et al., 2023/06. Nature medicine, 29 (6) pp. 1310-1312. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_079BED918172]
Optimal Delivery of Follow-Up Care Following Treatment for Adults Treated for Ewing Sarcoma.
Digklia A., Dolcan A., Kucharczyk M.A., Jones R.L., Napolitano A., 2023/06. Cancer management and research, 15 pp. 537-545. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A99279E44987]
 
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Im S.A., Gennari A., Park Y.H., Kim J.H., Jiang Z.F., Gupta S., Fadjari T.H., Tamura K., Mastura M.Y., Abesamis-Tiambeng MLT et al., 2023/06. ESMO open, 8 (3) p. 101541. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_833FEAFDA3E9]
 
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer.
Yoshino T., Cervantes A., Bando H., Martinelli E., Oki E., Xu R.H., Mulansari N.A., Govind Babu K., Lee M.A., Tan C.K. et al., 2023/06. ESMO open, 8 (3) p. 101558. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FC6A285A7C21]
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation.
Wischnewski V., Maas R.R., Aruffo P.G., Soukup K., Galletti G., Kornete M., Galland S., Fournier N., Lilja J., Wirapati P. et al., 2023/06. Nature cancer, 4 (6) pp. 908-924. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AF8A124C7797]
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.
de Mestier L., Resche-Rigon M., Dromain C., Lamarca A., La Salvia A., de Baker L., Fehrenbach U., Pusceddu S., Colao A., Borbath I. et al., 2023/06. Journal of neuroendocrinology, 35 (6) pp. e13311. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1A27AF92DDE2]
 
Simultaneous kinetics of oral vorinostat in plasma and cerebrospinal fluid in a patient with cutaneous T-cell lymphoma with CNS involvement.
Papadopoulou V., Degrauwe N., Decosterd L.A., Buclin T., Cairoli A., 2023/06. International journal of clinical pharmacology and therapeutics, 61 (6) pp. 270-272. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CC53A672C07F]
 
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.
Goldschmid H., Kluck K., Ball M., Kirchner M., Allgäuer M., Winter H., Herth F., Heußel C.P., Pullamsetti S.S., Savai R. et al., 2023/06. Lung cancer, 180 p. 107212. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_94DA50B976B3]
 
Tobacco cessation and the role of ESMO and medical oncologists: addressing the specific needs of cancer patients in times of the COVID-19 pandemic.
Krech R., Peters S., Kroemer H., Fu D., Giuliani R., Sehouli J., Ilbawi A., Prasad V., Ullrich A., 2023/06. ESMO open, 8 (3) p. 101579. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_348B9946FD46]
 
Cancer de la prostate à l’ère de la médecine de précision : un nouvel horizon [Prostate cancer in the era of precision medicine: a new horizon]
Nguyen-Ngoc T., Berthold D., Normand C., 2023/05/17. Revue medicale suisse, 19 (827) pp. 950-956. Peer-reviewed.
[DOI][Pmid][serval:BIB_1F5EA2E82D9D]
 
Cancer de l’endomètre : entre modernité et immunothérapie [Endometrial cancer in the crossroads of modernity and immunotherapy]
Giacomuzzi Moore B., Liapi A., Dolcan A., Kakourou A., Masmoudi S., Latifyan S., Sarivalasis A., 2023/05/17. Revue medicale suisse, 19 (827) pp. 944-949. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0D5FCD171133]
 
Cancers des glandes salivaires : nouvelles approches thérapeutiques [Salivary gland cancer: new therapeutic approaches]
Herrera Gomez R.G., Mederos N., Szturz P., Degrauwe N., Jankovic J., Cristina V., 2023/05/17. Revue medicale suisse, 19 (827) pp. 958-963. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_44E8BFC57D5D]
 
Carrières en oncologie et leadership féminin : les progrès sont-ils au point mort ?
Peters S., Addeo A., Aapro M., 2023/05/17. Revue medicale suisse, 19 (827) pp. 929-930. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_DF4B416E037D]
Influence of corticosteroid treatment on CXCR4 expression in DLBCL.
Martin S., Viertl D., Janz A., Habringer S., Keller U., Schottelius M., 2023/05/10. EJNMMI research, 13 (1) p. 40. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_18B6F1DF4772]
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe.
Kroese T.E., van Laarhoven HWM, Schoppman S.F., Deseyne PRAJ, van Cutsem E., Haustermans K., Nafteux P., Thomas M., Obermannova R., Mortensen H.R. et al., 2023/05. European journal of cancer, 185 pp. 28-39. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0D7216745F58]
Immunotherapy-based combinations in metastatic NSCLC.
Desai A., Peters S., 2023/05. Cancer treatment reviews, 116 p. 102545. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_74C72B664E9F]
 
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance.
Hwang M., Chia Y.L., Zheng Y., Chen C.C., He J., Song X., Zhou D., Goldberg S.B., Siu L.L., Planchard D. et al., 2023/05. British journal of clinical pharmacology, 89 (5) pp. 1601-1616. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_49EDEBE6BC65]
Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography Imaging.
Abler D., Courlet P., Dietz M., Gatta R., Girard P., Munafo A., Wicky A., Jreige M., Guidi M., Latifyan S. et al., 2023/05. JCO clinical cancer informatics, 7 pp. e2200126. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_D61806C1E839]
 
Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
Kris M.G., Mitsudomi T., Peters S., 2023/04/28. Translational lung cancer research, 12 (4) pp. 824-836. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_68C5CE6F566B]
Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA).
Iivanainen S., Baird A.M., Balas B., Bustillos A., Castro Sanchez A.Y., Eicher M., Golding S., Mueller-Ohldach M., Reig M., Welslau M. et al., 2023/04/19. BMJ open, 13 (4) pp. e063242. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_977B9654EEC3]
 
Baseline 18F-FDG PET/CT Radiomics in Classical Hodgkin’s Lymphoma: The Predictive Role of the Largest and the Hottest Lesions.
Triumbari EKA, Gatta R., Maiolo E., De Summa M., Boldrini L., Mayerhoefer M.E., Hohaus S., Nardo L., Morland D., Annunziata S., 2023/04/11. Diagnostics, 13 (8) p. 1391. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C94C68D79B02]
 
A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl).
Palmerini E., Gambarotti M., Italiano A., Nathenson M.J., Ratan R., Dileo P., Provenzano S., Jones R.L., DuBois S.G., Martin-Broto J. et al., 2023/04. European journal of cancer, 183 pp. 11-23. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_514E63DE5157]
 
Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.
Linardou H., Adjei A.A., Bajpai J., Banerjee S., Berghoff A.S., Mathias C.C., Choo S.P., Dent R., Felip E., Furness AJS et al., 2023/04. ESMO open, 8 (2) p. 100781. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F95E2DE28E52]
 
Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT).
Gridelli C., Peters S., Velcheti V., Attili I., de Marinis F., 2023/04. ESMO open, 8 (2) p. 101192. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6ABA6C8DB138]
 
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Hendriks L.E., Kerr K.M., Menis J., Mok T.S., Nestle U., Passaro A., Peters S., Planchard D., Smit E.F., Solomon B.J. et al., 2023/04. Annals of oncology, 34 (4) pp. 358-376. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0E714965871B]
 
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Hendriks L.E., Kerr K.M., Menis J., Mok T.S., Nestle U., Passaro A., Peters S., Planchard D., Smit E.F., Solomon B.J. et al., 2023/04. Annals of oncology, 34 (4) pp. 339-357. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2DAD09CAD00B]
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Joerger M., Hundsberger T., Haefliger S., von Moos R., Hottinger A.F., Kaindl T., Engelhardt M., Marszewska M., Lane H., Roth P. et al., 2023/04. Investigational new drugs, 41 (2) pp. 267-275. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8938B103AA5D]
 
The SERENITY study: online Mindfulness-Based Cancer Recovery (e-MBCR) program for women living with breast and gynecological cancer—protocol for a pilot effectiveness-implementation randomized trial
Gaignard Marie-Estelle, Stanic Jelena, Bodmer Alexandre, Zaman Khalil, Sarivalasis Apostolos, Labidi-Galy Intidhar, Jermann Francoise, Di Marco Mariagrazia, Ljuslin Michael, Ryser Stephan et al., 2023/04. Journal of Psychosocial Oncology Research & Practice, 5 (2).
[DOI][serval:BIB_837DAB9F23E5]
Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.
Cloitre M., Valerio M., Mampuya A., Rakauskas A., Berthold D., Tawadros T., Meuwly J.Y., Heym L., Duclos F., Vallet V. et al., 2023/04/01. The British journal of radiology, 96 (1145) p. 20220803. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CB3AC2C2AFDE]
 
A neutrophil response linked to tumor control in immunotherapy.
Gungabeesoon J., Gort-Freitas N.A., Kiss M., Bolli E., Messemaker M., Siwicki M., Hicham M., Bill R., Koch P., Cianciaruso C. et al., 2023/03/30. Cell, 186 (7) pp. 1448-1464.e20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_75BDBCD58180]
 
Le régime cétogène : efficace contre le cancer ? [Is ketogenic diet effective against cancer ?]
Tankeu A.T., Barigou M., Pedro R., De Micheli R., Bodmer A., Genton L., Collet T.H., Tran C., 2023/03/22. Revue medicale suisse, 19 (819) pp. 576-580. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E4266B1D898E]
QuantImage v2: a comprehensive and integrated physician-centered cloud platform for radiomics and machine learning research.
Abler D., Schaer R., Oreiller V., Verma H., Reichenbach J., Aidonopoulos O., Evéquoz F., Jreige M., Prior J.O., Depeursinge A., 2023/03/22. European radiology experimental, 7 (1) p. 16. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EBB87EC8BBD4]
 
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
Mamot C., Wicki A., Hasler-Strub U., Riniker S., Li Q., Holer L., Bärtschi D., Zaman K., von Moos R., Dedes K.J. et al., 2023/03/06. Scientific reports, 13 (1) p. 3705. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8ADF8CFC0053]
 
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
de Langen A.J., Johnson M.L., Mazieres J., Dingemans A.C., Mountzios G., Pless M., Wolf J., Schuler M., Lena H., Skoulidis F. et al., 2023/03/04. Lancet, 401 (10378) pp. 733-746. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_610E00846F6E]
 
The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer.
Voutsadakis I.A., Digklia A., 2023/03/03. Current issues in molecular biology, 45 (3) pp. 2105-2120. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5BA72940A3F2]
 
Assoziation von KRAS/STK11/KEAP1 Mutationen und Outcome in der POSEIDON Studie: Durvalumab+/− Tremelimumab+Chemotherapie beim metastasierten NSCLC (mNSCLC)
Reinmuth N, Peters S, Cho B, Luft A, Alatorre-Alexander J, Geater S, Kim S, Ursol G, Hussein M, Lim F et al., 2023/03. dans 63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
[DOI][WoS][serval:BIB_BEC283C28682]
 
Clear cell sarcoma: state-of-the art and perspectives.
Wetterwald L., Riggi N., Kyriazoglou A., Dei Tos G., Dei Tos A., Digklia A., 2023/03. Expert review of anticancer therapy, 23 (3) pp. 235-242. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E565DF943C91]
Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.
Voutsadakis I.A., Stravodimou A., 2023/03. Anticancer research, 43 (3) pp. 967-981. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3961434FC488]
Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1.
Robert C., Lebbé C., Lesimple T., Lundström E., Nicolas V., Gavillet B., Crompton P., Baroudjian B., Routier E., Lejeune F.J., 2023/03/01. Clinical cancer research, 29 (5) pp. 858-865. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_04775354DA15]
 
Single Seminal Vesicle Metastasis From Dorsal Melanoma Detected by 18 F-FDG PET/CT and Confirmed by Biopsy.
Testart Dardel N., Isenborghs E., Valerio M., Michielin O., Schaefer N., 2023/03/01. Clinical nuclear medicine, 48 (3) pp. e151-e152. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E552B0535E6B]
Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
Krebs F.S., Moura B., Missiaglia E., Aedo-Lopez V., Michielin O., Tsantoulis P., Bisig B., Trimech M., Zoete V., Homicsko K., 2023/02/24. International journal of molecular sciences, 24 (5) p. 4520. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E3A48A3138B7]
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Johnson M.L., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Laktionov K., Kim S.W., Ursol G., Hussein M., Lim F.L. et al., 2023/02/20. Journal of clinical oncology, 41 (6) pp. 1213-1227. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_50248B9218E8]
Dendritic cells direct circadian anti-tumour immune responses.
Wang C., Barnoud C., Cenerenti M., Sun M., Caffa I., Kizil B., Bill R., Liu Y., Pick R., Garnier L. et al., 2023/02. Nature, 614 (7946) pp. 136-143. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_33489F389D05]
Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure.
Raoul J.L., Moreau-Bachelard C., Gilabert M., Edeline J., Frénel J.S., 2023/02. ESMO open, 8 (1) p. 100880. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8D75F775A9EA]
 
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer.
Koppikar S., Oaknin A., Babu K.G., Lorusso D., Gupta S., Wu L.Y., Rajabto W., Harano K., Hong S.H., Malik R.A. et al., 2023/02. ESMO open, 8 (1) p. 100774. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_236602D3C3F5]
Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
Voutsadakis I.A., Digklia A., 2023/02. Chinese clinical oncology, 12 (1) p. 2. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_173A16DC9A8B]
 
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in Older Patients: Are New Agents Bringing New Hope?
Cossu Rocca M., Lorini L., Szturz P., Bossi P., Vermorken J.B., 2023/02. Drugs & aging, 40 (2) pp. 135-143. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4C168665F905]
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N., Bar J., Garrido P., Garassino M.C., McDonald F., Mornex F., Filippi A.R., Smit HJM, Peters S., Field J.K. et al., 2023/02. Journal of thoracic oncology, 18 (2) pp. 181-193. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D36FA0602240]
Lymph Node Involvement in Recurrent Serous Borderline Ovarian Tumors: Current Evidence, Controversies, and a Review of the Literature.
Wetterwald L., Sarivalasis A., Liapi A., Mathevet P., Achtari C., 2023/01/31. Cancers, 15 (3) p. 890. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_27A10B3161E6]
 
Oncologie : ce qui a changé en 2022 [Oncology: what's new in 2022]
Nguyen-Ngoc T., Abdelhamid K., Degrauwe N., Galland S., Serena A., Christofis M., Mederos N., Bouchaab H., Diciolla A., Dris N. et al., 2023/01/18. Revue medicale suisse, 19 (N° 809-10) pp. 52-57. Peer-reviewed.
[DOI][Pmid][serval:BIB_FAF585D3813B]
Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors.
Álvarez-Prado Á.F., Maas R.R., Soukup K., Klemm F., Kornete M., Krebs F.S., Zoete V., Berezowska S., Brouland J.P., Hottinger A.F. et al., 2023/01/17. Cell reports. Medicine, 4 (1) p. 100900. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B718E4D7ABEC]
 
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).
Hoang-Xuan K., Deckert M., Ferreri AJM, Furtner J., Gallego Perez-Larraya J., Henriksson R., Hottinger A.F., Kasenda B., Lefranc F., Lossos A. et al., 2023/01/05. Neuro-oncology, 25 (1) pp. 37-53. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E39A5D50A7EF]
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
Bandiera C., Locatelli I., Courlet P., Cardoso E., Zaman K., Stravodimou A., Dolcan A., Sarivalasis A., Zurcher J.P., Aedo-Lopez V. et al., 2023/01/03. Cancers, 15 (1) p. 316. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2263B25B85EB]
 
An interprofessional medication adherence program to optimize adherence to oral anticancer therapies: a randomized-controlled trial
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2023., 26th International Society for Medication Adherence (ESPACOMP) Conference p. 269 dans International Journal of Clinical Pharmacy. Peer-reviewed.
[DOI][Pmid][serval:BIB_944A7B3041CF]
 
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.
Peters S., Letovanec I., Mauer M., Dafni U., Ejedepang D., Biernat W., Bubendorf L., Warth A., Pokharel S., Reinmuth N. et al., 2023/01. Lung cancer, 175 pp. 141-151. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_39ABDF31542A]
Diagnostic challenges and prognostic implications of extranodal extension in head and neck cancer: a state of the art review and gap analysis.
Henson C.E., Abou-Foul A.K., Morton D.J., McDowell L., Baliga S., Bates J., Lee A., Bonomo P., Szturz P., Nankivell P. et al., 2023. Frontiers in oncology, 13 p. 1263347. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_92E590E95450]
Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature.
Liapi A., Atat C., Dunet V., Sarivalasis A., 2023. SAGE open medical case reports, 11 pp. 2050313X231176401. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8E786969EDB9]
Editorial: Head and neck cancer in the elderly.
Szturz P., Vermorken J.B., 2023. Frontiers in oncology, 13 p. 1218274. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BEFAA76D6472]
Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
Hasler-Strub U., Mueller A., Li Q., Thuerlimann B., Ribi K., Gerber S., von Moos R., Fehr M., Rochlitz C., Zaman K. et al., 2023/01. Journal of geriatric oncology, 14 (1) p. 101372. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1D987C9B9D86]
Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.
Margalit O., Harmsen W.S., Shacham-Shmueli E., Voss M.M., Boursi B., Wagner A.D., Cohen R., Olswold C.L., Saltz L.B., Goldstein D.A. et al., 2023/01. European journal of cancer, 178 pp. 162-170. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0A89637C6063]
 
Expanding Therapeutic Frontiers: CEACAM5 as a Therapeutic Target in Lung Cancer
Peters Solange, 2023/01. Oncology-New York, 37 (1) pp. 40-42.
[WoS][serval:BIB_ED01F2B48586]
 
High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
Dziadziuszko R., Peled N., Mok T., Peters S., Aix S.P., Alatorre-Alexander J., Vicuna B.D., Maclennan M., Bhagawati-Prasad V., Shagan S.M. et al., 2023. Contemporary oncology, 27 (4) pp. 217-223. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2106BCEFA0A7]
 
Imaging assessment of toxicity related to immune checkpoint inhibitors.
Berz A.M., Boughdad S., Vietti-Violi N., Digklia A., Dromain C., Dunet V., Duran R., 2023. Frontiers in immunology, 14 p. 1133207. Peer-reviewed.
[DOI][Pmid][serval:BIB_8384233B2788]
Interactive process mining of cancer treatment sequences with melanoma real-world data.
Wicky A., Gatta R., Latifyan S., Micheli R., Gerard C., Pradervand S., Michielin O., Cuendet M.A., 2023. Frontiers in oncology, 13 p. 1043683. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DD5F930248D5]
 
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
Bakouny Ziad, Labaki Chris, Grover Punita, Awosika Joy, Gulati Shuchi, Hsu Chih-Yuan, Alimohamed Saif I., Bashir Babar, Berg Stephanie, Bilen Mehmet A. et al., 2023/01/01. JAMA Oncology, 9 (1) p. 128.
[DOI][WoS][Pmid][serval:BIB_41138DAA93B2]
 
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project.
Cazzaniga M.E., Ciaccio A., Danesi R., Duhoux F.P., Girmenia C., Zaman K., Lindman H., Luppi F., Mavroudis D., Paris I. et al., 2023. Frontiers in oncology, 13 p. 1247270. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_60FF24136E2E]
Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy.
Mastelic-Gavillet B., Sarivalasis A., Lozano L.E., Lofek S., Wyss T., Melero I., de Vries IJM, Harari A., Romero P., Kandalaft L.E. et al., 2023. Frontiers in immunology, 14 p. 1119371. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_93460C0AF320]
 
Management and outcomes of brain metastases from pancreatic adenocarcinoma: a pooled analysis and literature review.
Gouton E., Gilabert M., Launay S., Loir E., Tyran M., Rochigneux P., Turrini O., Garnier J., Mitry E., Chanez B., 2023. Frontiers in oncology, 13 p. 1326676. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_24AB2032ACA9]
 
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.
Haber P.K., Castet F., Torres-Martin M., Andreu-Oller C., Puigvehí M., Miho M., Radu P., Dufour J.F., Verslype C., Zimpel C. et al., 2023/01. Gastroenterology, 164 (1) pp. 72-88.e18. Peer-reviewed.
[DOI][Pmid][serval:BIB_5E664B01B65D]
Precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: A perspective.
Briki M., André P., Thoma Y., Widmer N., Wagner A.D., Decosterd L.A., Buclin T., Guidi M., Carrara S., 2023. Pharmaceutics, 15 (4) p. 1283. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A82A8DDE8796]
 
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
Paz-Ares L.G., Ciuleanu T.E., Pluzanski A., Lee J.S., Gainor J.F., Otterson G.A., Audigier-Valette C., Ready N., Schenker M., Linardou H. et al., 2023/01. Journal of thoracic oncology, 18 (1) pp. 79-92. Peer-reviewed.
[DOI][Pmid][serval:BIB_0FB9CAD0B375]
Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer.
Kroese T.E., van Rossum PSN, Nilsson M., Lordick F., Smyth E.C., Rosati R., Nafteux P., D'Ugo D., Chaudry M.A., Polkowkski W. et al., 2023/01. European journal of surgical oncology, 49 (1) pp. 21-28. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F9C8EA647E0C]
2022
Estimating the Prevalence of a True Oligometastatic Disease.
Szturz P., Bonomo P., Vermorken J.B., 2022/12/30. Cancers, 15 (1) p. 214. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_56F0255A14F5]
Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma.
Gautron Moura B., Gerard C.L., Testart N., Caikovski M., Wicky A., Aedo-Lopez V., Berthod G., Homicsko K., Prior J.O., Dromain C. et al., 2022/12/21. Cancers, 15 (1) p. 31. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0AF72365A8C3]
A differential process mining analysis of COVID-19 management for cancer patients.
Cuendet M.A., Gatta R., Wicky A., Gerard C.L., Dalla-Vale M., Tavazzi E., Michielin G., Delyon J., Ferahta N., Cesbron J. et al., 2022/12/07. Frontiers in oncology, 12 p. 1043675. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_98AD494947E5]
Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib.
Dziadziuszko R., Peters S., Ruf T., Cardona A., Guerini E., Kurtsikidze N., Smoljanovic V., Planchard D., 2022/12. ESMO open, 7 (6) p. 100612. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6AC5881EE42A]
Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer.
Aapro M., Cardoso F., Curigliano G., Eniu A., Gligorov J., Harbeck N., Mueller A., Pagani O., Paluch-Shimon S., Senkus E. et al., 2022/12. Breast, 66 pp. 145-156. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BADA4FB4DFBC]
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.
Rüschoff J.H., Haberecker M., Tsourti Z., Nackaerts K., de Perrot M., Brcic L., Nadal E., Tsimpoukis S., Gray S.G., Ampollini L. et al., 2022/12. Modern pathology, 35 (12) pp. 1888-1899. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_21A2AA0732D5]
 
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
Furrer K., Weder W., Eboulet E.I., Betticher D., Pless M., Stupp R., Krueger T., Perentes J.Y., Schmid R.A., Lardinois D. et al., 2022/12. The Journal of thoracic and cardiovascular surgery, 164 (6) pp. 1587-1602.e5. Peer-reviewed.
[DOI][Pmid][serval:BIB_85FE22283C7C]
 
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Haanen J., Obeid M., Spain L., Carbonnel F., Wang Y., Robert C., Lyon A.R., Wick W., Kostine M., Peters S. et al., 2022/12. Annals of oncology, 33 (12) pp. 1217-1238. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F3804F73BCD6]
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Schettini F., Venturini S., Giuliano M., Lambertini M., Pinato D.J., Onesti C.E., De Placido P., Harbeck N., Lüftner D., Denys H. et al., 2022/12. Cancer treatment reviews, 111 p. 102468. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4B4B16BC3FE0]
 
Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial.
Panje C., Hayoz S., Eisterer W., Hess V., Thuss-Patience P., Schacher S., Dürr D., Wagner A.D., Girschikofsky M., Eboulet E. et al., 2022/12. European journal of cancer, 177 pp. 186-193. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F9CAE3DCD0B4]
 
Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort.
Bubendorf L., Zoche M., Dafni U., Rüschoff J.H., Prince S.S., Marti N., Stavrou A., Kammler R., Finn S.P., Moch H. et al., 2022/12. Lung cancer, 174 pp. 27-35. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4F9A876B9A34]
Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Röhrig U.F., Majjigapu S.R., Vogel P., Reynaud A., Pojer F., Dilek N., Reichenbach P., Ascenção K., Irving M., Coukos G. et al., 2022/12. Journal of enzyme inhibition and medicinal chemistry, 37 (1) pp. 1773-1811. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EF494F840FDA]
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Garbe C., Keim U., Amaral T., Berking C., Eigentler T.K., Flatz L., Gesierich A., Leiter U., Stadler R., Sunderkötter C. et al., 2022/11/10. Journal of clinical oncology, 40 (32) pp. 3741-3749. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_552F42A6F0C7]
Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
Camviel Nicolas, Wolf Benita, Croce Giancarlo, Gfeller David, Zoete Vincent, Arber Caroline, 2022/11. Journal for ImmunoTherapy of Cancer, 10 (11) pp. e005091. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_F15484E457D0]
 
ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe
Vaz-Luis I., Masiero M., Cavaletti G., Cervantes A., Chlebowski R.T., Curigliano G., Felip E., Ferreira A.R., Ganz P.A., Hegarty J. et al., 2022/11. Annals of Oncology, 33 (11) pp. 1119-1133.
[DOI][Pmid][serval:BIB_6B7220949D26]
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
Cortellini A., Dettorre G.M., Dafni U., Aguilar-Company J., Castelo-Branco L., Lambertini M., Gennatas S., Angelis V., Sita-Lumsden A., Rogado J. et al., 2022/11. Journal for immunotherapy of cancer, 10 (11) pp. e005732. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_43EB088625EB]
Patients' experiences with cancer care in Switzerland: Results of a multicentre cross-sectional survey.
Arditi C., Eicher M., Colomer-Lahiguera S., Bienvenu C., Anchisi S., Betticher D., Dietrich P.Y., Duchosal M., Peters S., Peytremann-Bridevaux I., 2022/11. European journal of cancer care, 31 (6) pp. e13705. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0C98FBD02368]
 
Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M., Högner A., Wagner A.D., Obermannova R., Alsina M., Thuss-Patience P., van Laarhoven H., Smyth E., 2022/11. European journal of cancer, 176 pp. 13-29. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6378883AE7D4]
 
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.
Papachristofilou A., Bedke J., Hayoz S., Schratzenstaller U., Pless M., Hentrich M., Krege S., Lorch A., Aebersold D.M., Putora P.M. et al., 2022/11. The Lancet. Oncology, 23 (11) pp. 1441-1450. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_989E8E47D384]
What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature.
McNamara M.G., Bridgewater J., Goyal L., Jacobs T., Wagner A.D., Goldstein D., Shroff R., Moehler M., Lowery M., Bekaii-Saab T. et al., 2022/10/26. BMJ open, 12 (10) pp. e064954. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F26107797F0E]
 
Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
Rüschoff Jan Hendrik, Haberecker Martina, Tsourti Zoi, Nackaerts Kristiaan, de Perrot Marc, Brcic Luka, Nadal Ernest, Tsimpoukis Sotirios, Gray Steven G., Ampollini Luca et al., 2022/10/17..
[DOI][WoS][Pmid][serval:BIB_098139D32FFB]
 
Minus Times Minus Equals Plus.
Haanen J., Peters S., 2022/10/10. Journal of clinical oncology, 40 (29) pp. 3453-3455. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5A1E1EED8DF6]
 
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.
Felip E., Smit E.F., Molina-Vila M.A., Dafni U., Massuti B., Berghmans T., de Marinis F., Passiglia F., Dingemans A.C., Cobo M. et al., 2022/10. Lung cancer, 172 pp. 94-99. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A1D5ACC49E2E]
Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries.
Soo R., Mery L., Bardot A., Kanesvaran R., Keong T.C., Pongnikorn D., Prasongsook N., Hutajulu S.H., Irawan C., Manan A.A. et al., 2022/10. ESMO open, 7 (5) p. 100560. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2C2E664EBE7E]
First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer.
Digklia A., Boughdad S., Homicsko K., Dromain C., Trimech M., Dolcan A., Peters S., Prior J., Schaefer N., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e005383. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_923D116CD173]
 
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
Davis E.J., Martin-Liberal J., Kristeleit R., Cho D.C., Blagden S.P., Berthold D., Cardin D.B., Vieito M., Miller R.E., Hari Dass P. et al., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e004235. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D7C84C98BDB5]
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.
Boni V., Pistilli B., Braña I., Shapiro G.I., Trigo J., Moreno V., Castellano D., Fernández C., Kahatt C., Alfaro V. et al., 2022/10. ESMO open, 7 (5) p. 100571. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B3A5E089EDDA]
 
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M., Paz-Ares L., Marreaud S., Dafni U., Oselin K., Havel L., Esteban E., Isla D., Martinez-Marti A., Faehling M. et al., 2022/10. The Lancet. Oncology, 23 (10) pp. 1274-1286. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AB45342CF3A7]
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
Coukos A., Vionnet J., Obeid M., Bouchaab H., Peters S., Latifyan S., Wicky A., Michielin O., Chtioui H., Moradpour D. et al., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e005635. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F836C2B098EA]
Towards a national strategy for digital pathology in Switzerland.
Janowczyk A., Baumhoer D., Dirnhofer S., Grobholz R., Kipar A., de Leval L., Merkler D., Michielin O., Moch H., Perren A. et al., 2022/10. Virchows Archiv, 481 (4) pp. 647-652. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_329EB5DFD086]
Organoids: A New Chapter in Sarcoma Diagnosis and Treatment.
Psilopatis I., Kokkali S., Palamaris K., Digklia A., Vrettou K., Theocharis S., 2022/09/24. International journal of molecular sciences, 23 (19) p. 11271. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E6378E1D11BD]
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Ascierto P.A., Agarwala S.S., Blank C., Caracò C., Carvajal R.D., Ernstoff M.S., Ferrone S., Fox B.A., Gajewski T.F., Garbe C. et al., 2022/09/04. Journal of translational medicine, 20 (1) p. 391. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4E798A46CDF9]
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S., Dziadziuszko R., Morabito A., Felip E., Gadgeel S.M., Cheema P., Cobo M., Andric Z., Barrios C.H., Yamaguchi M. et al., 2022/09. Nature medicine, 28 (9) pp. 1831-1839. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D64BF6CDC58E]
Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.
Adamina M., Warlaumont M., Berger M.D., Däster S., Delaloye R., Digklia A., Gloor B., Fritsch R., Koeberle D., Koessler T. et al., 2022/09/01. Cancers, 14 (17) p. 4275. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_62CF2A596AB9]
 
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group.
Sclafani F., Fontana E., Wyrwicz L., Wagner A.D., Valle J.W., Smyth E., Peeters M., Obermannova R., Neuzillet C., Lutz M.P. et al., 2022/09. Clinical colorectal cancer, 21 (3) pp. 188-197. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_700C97DDB27C]
 
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches.
Cortiula F., Reymen B., Peters S., Van Mol P., Wauters E., Vansteenkiste J., De Ruysscher D., Hendriks LEL, 2022/09. Annals of oncology, 33 (9) pp. 893-908. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2C9FA7FE4F90]
 
Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts.
Quaas A., Biesma H.D., Wagner A.D., Verheij M., van Berge Henegouwen M.I., Schoemig-Markiefka B., Pamuk A., Zander T., Siemanowski J., Sikorska K. et al., 2022/09. European journal of cancer, 173 pp. 95-104. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3F864F08541F]
 
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
Le Rhun E., Oppong F.B., Vanlancker M., Stupp R., Nabors B., Chinot O., Wick W., Preusser M., Gorlia T., Weller M., 2022/09/01. Neuro-oncology, 24 (9) pp. 1533-1545. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C41F4087F4FB]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University